Nov 24, 2020

Dr. Marik’s research can be found here:

COVID19CRITICALCARE.COM

HERE IS THE PLAN TO GET US OUT OF THIS #COVID19 WAR

• NO lockdowns
• NO waiting for vaccines
• Reverses cases in weeks

– Michael Mina, MD, PhD
Assistant Professor of Epidemiology, Harvard T.H. Chan School of Public Health; Core Faculty, Center for Communicable Disease Dynamics

https://mobile.twitter.com/michaelmina_lab/status/1328873625894719489

(Skip audio forward to 3:07)

Analyzing locations with similar populations:

LOCATION : POP : INFECTIONS : DEATHS

UK : 67mil : 1,830,000 : 64,000
Thailand : 67mil : 4,000 : 60

Florida: 22mil : 1,125,000 : 20,133
Taiwan : 23mil : 736 : 7

Arizona : 7.5mil : 408,000 : 7,000
Hong Kong : 7.5mil : 7,500 : 116

Mexico ; 126mil ; 1,250,000 ; 113,000
Japan : 126mil : 177,000 : 2,000

Brazil : 210mil : 6,008,000 : 181,000
Nigeria ; 207mil ; 72,000 ; 1,194

India : 1.4bil : 9.8mil: 143,000
China : 1.4bil : 92,000 : 4,000

Interviewee is Joel Wallach, a well respected naturopathic doctor & veterinarian. He says the difference in these locations is the gluten in the diets.

I’ll let you decide. I believe diet is a huge factor, but I think it’s more complex. To live more like Asia the Western nations need to:

• Increase fresh vegetables, fruits, legumes (beans), nuts, whole grains (irrespective of gluten).
• Reduce consumption of animal products.
• Increase mobility (exercise).
• Relax/reduce stress.

HHS current hospitalization data is always available here:

https://protect-public.hhs.gov/pages/hospital-capacity

On 11/23/2020 it shows 60.62% ICU occupancy across the US (not just covid ICU).

[ UPDATE: 12/4/2020 shows 60.14% ICU occupancy ]

[ UPDATE: 12/9/2020 shows 63.57% ICU occupancy ]

[ UPDATE: 12/15/2020 shows 63.87% ICU occupancy ]

[ UPDATE: 12/29/2020 shows 61.15% ICU occupancy ]

[ UPDATE: 1/4/2020 shows 63.18% ICU occupancy ]

The map shows state by state breakdowns.

Check back often…

Note: You may also Google NY Times ICU occupancy to check your local stats.

https://www.nytimes.com/interactive/2020/us/covid-hospitals-near-you.html

However, the Times acquires their figures from the HHS. The HHS website link is provided above.

When I checked today the Times’ estimated national ICU occupancy figure (levels reported over the seven days from Dec. 4 through Dec. 10)

************

************

was 14.13% higher than HHS Data Hub’s national ICU occupancy.

(Perhaps one or the other has not recently updated.)

https://youtu.be/PXh1yflndVE

https://covid19criticalcare.com/

Youtube has censored this ivermectin video, but here are great interviews about it: https://projectwaistline.com/?p=25612

https://youtu.be/MEk-VOufVGQ

Dec 4, 2020

RESEARCH GROUP:

https://covid19criticalcare.com/

NOTE:

I just remembered this story last year of a man’s cancer going into remission using the de-wormer benzimidazole. http://projectwaistline.com/?p=17526

The ivermectin we’ve been discussing is described as a treatment for parasitic worms. ARE THESE TWO RELATED??

Here’s a 2016 paper describing the use of benzimidazole as an ANTIVIRAL.
https://jvi.asm.org/content/90/19/8422

https://youtube.com/watch?v=Tq8SXOBy-4w

10 minute 10 second video from Dec 8, 2020 discussing the positive outcomes using the repurposed drug Ivermectin (earned a Nobel Prize for treatment of parasitic diseases in 2015).

Here is a research paper published in June:

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

2 hours 16 minute video (Senate hearing I, Nov 19, 2020 )

2 hours 40 minutes (Senate hearing II, Dec 8, 2020)

Senate considers early outpatient covid treatment.

On December 1, 2020

* Dr. Wolfgang Wodarg, chairman of the Health Committee of PACE (Parliamentary Assembly of the Council of Europe), medical doctor, epidemiologist, specialist in lung disease and environmental medicine

AND

* Dr. Michael Yeadon, PhD in respiratory pharmacology and a former leader in pharmaceutical corporations

filed an application with the EMA, the European Medicine Agency responsible for EU-wide drug approval, for the immediate suspension of all SARS CoV 2 vaccine studies, in particular the BioNtech/Pfizer study on BNT162b (EudraCT number 2020-002641-42).

For your consideration… we are as the Bereans. We will not walk blindly into the future. We will search, research & consider.

These were more noble than those in Thessalonica, in that they received the word with all readiness of mind, and searched the scriptures daily, whether those things were so.

(Acts 17:10,11)

Click here for reproductive questions

AND

Click here for social equity issues

In order to better understand CFR we consider definition in this link from Britannica.

Case fatality rate, also called case fatality risk or case fatality ratio, in epidemiology, the proportion of people who die from a specified disease among all individuals diagnosed with the disease over a certain period of time.

.

We take current stats from WORLDOMETER and apply the definition for a rough estimate:

Case Fatality Rate for USA

Actual Cases with an outcome as of Dec 9 = estimated actual recovered (9,088,387) + estimated actual deaths (293,496) = 9,381,883

Case Fatality Rate (CFR) = Deaths / Cases = 293,496 / 9,381,883 = 0.03128327223 = 3.1%

Our crude estimate shows that approximately 96.9% of people infected with SARS-CoV-2 recover (100% – 3.1% = 96.9%). Keep in mind covid deaths are very likely overstated, and covid cases are very likely underreported.

This calculation includes all cases, of all ages, with & without comorbidities.

Had we used the number of USA cases at WORLDOMETER, 15,607,655 as of Dec 9, our survival rate would look much higher: 293,496 / 15,607,655 = 0.019 = 1.9%, yielding a survival rate of 98.1%. But the 96.9% survival rate calculated above is a much more conservative figure.

Dec 4, 2020

(English subtitles)

https://youtu.be/nO1uTHpPXRY

Suchrid Bhakdi studied at the Universities of Bonn, Gießen, Mainz and Copenhagen, and at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg.

He studied medicine at the University of Bonn from 1963 to 1970, during part of which (from 1966 to 1970) he was a scholarship holder of the German Academic Exchange Service. Bhakdi worked for a while as a private assistant to the internal medicine specialist Walter Siegenthaler. In February 1971 he received his doctorate in medicine. From 1972 to 1974, he held a scholarship from the Max Planck Society at the Max Planck Institute of Immunobiology in Freiburg. From 1974 to 1976, he also received a scholarship from the Alexander von Humboldt Foundation at the Max Planck Institute for Immunobiology in Freiburg.

After a one-year stay at the University of Copenhagen, he worked from 1977 to 1990 at the Institute of Medical Microbiology at the Justus Liebig University in Gießen. In July 1979 he habilitated. He was appointed C2 professor in 1982 and C3 professor of medical microbiology in 1987 before being appointed to the University of Mainz in 1990. From 1991 he headed the Institute of Medical Microbiology and Hygiene as a C4 professor.

Bhakdi retired on 1 April 2012. Since 2016 he has been a visiting scholar at the University of Kiel.